ITGAL
ENSG00000005844
Target class
Adhesion
Chromosome
16
Approved drugs
2
Clinical candidates (approved and in development)
4
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- Yes
- Target name
- ITGAL
- Gene name
- Integrin subunit alpha L
- Gene symbol
- ITGAL
- Previous gene symbols
- CD11A
- Protein name
- Integrin alpha-L (CD11 antigen-like family member A) (Leukocyte adhesion glycoprotein LFA-1 alpha chain) (LFA-1A) (Leukocyte function-associated molecule 1 alpha chain) (CD antigen CD11a)
- HNA-5
- LFA-1
- LFA1A
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Integrin alpha subunits|MicroRNA protein coding host genes|Human neutrophil antigens
- Target class
- Adhesion
- Target type
- Human gene
- Tissues expressed in
- 38
- Highest tissue expression
- 111.53
- Tissue specificity (Gini)
- 0.781
- Tissue specificity (tau)
- 0.94
- KEGG gene identifiers
- hsa:3683
- Protein interaction confidence
- 0.874388
- Protein interaction partners
- 67
- R-HSA-198933
- R-HSA-202733
- R-HSA-216083
- R-HSA-6798695
- R-HSA-8949275
- End position
- 30523567
- Start position
- 30472658
- Chromosome
- 16
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Membrane raft . Note=Upon antigen recognition by the TCR, is recruited to lipid rafts (PubMed:15684041). .
- PubMed 15684041
- PubMed 16301335
- Tissue specificity (tau)
- 0.939773
- Expression inequality (Gini)
- 0.780981
Expression in transcripts per million
- Spleen
- 111.53
- Whole Blood
- 110.59
- Cells - EBV-transformed lymphocytes
- 74.61
- Lung
- 36.26
- Small Intestine - Terminal Ileum
- 22.25
Expression in transcripts per million
- Spleen111.53
- Whole Blood110.59
- Cells - EBV-transformed lymphocytes74.61
- Lung36.26
- Small Intestine - Terminal Ileum22.25
- Liver7.49
- Fallopian Tube6.93
- Adipose - Visceral (Omentum)5.6
- Bladder5.06
- Colon - Transverse5.01
- Cervix - Endocervix4.69
- Thyroid4.69
- Adipose - Subcutaneous4.05
- Minor Salivary Gland4.02
- Vagina3.91
- Prostate3.86
- Brain - Spinal cord (cervical c-1)3.74
- Breast - Mammary Tissue3.63
- Artery - Coronary3.47
- Stomach3.25
- Nerve - Tibial3.12
- Cervix - Ectocervix3.08
- Artery - Aorta2.76
- Uterus2.66
- Esophagus - Mucosa2.49
And 29 more, listed on the interactive page.
- GO:0002291
- GO:0007157
- GO:0007158
- GO:0007159
- GO:0007160
- GO:0033627
- GO:0033631
- GO:0035683
- GO:0043113
- GO:0005886
- GO:0008305
- GO:0009986
- GO:0016020
- GO:0034687
- GO:0035579
- GO:0045121
- GO:0070062
- GO:0004895
- GO:0005515
- GO:0030369
- GO:0050839
Related records
Trials (74)
- A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis
- A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
- A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis
- A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
- A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
- A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies
- A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
- A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
- A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation
- A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies
- A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)
- A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
- A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
- A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies
- A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
- A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis
- A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
- A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet
- A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
Drugs (5)
- Efalizumab Integrin alpha-L/beta-2 (LFA-1) inhibitor
- Lifitegrast Integrin alpha-L/beta-2 (LFA-1) antagonist
- Lifitegrast sodium Integrin alpha-L/beta-2 (LFA-1) antagonist
- Odulimomab Leukocyte adhesion glycoprotein LFA-1 alpha inhibitor
- Rovelizumab Integrin alpha-L/beta-2 (LFA-1) antagonist